CELLAVISION AB [CBOE] overview

The information was submitted for publication at 08.20 CET on July 16, 2020 1 April -30 June 2020 Net sales increased by 5% to SEK 118.0 million (112.4). Sales decreased organically by 15% (+18). EBITDA amounted to SEK 36.2 million (41.3). EBITDA margin amounted to 31% (37). Profit before tax amounted to SEK 34.4 million (37.9). Earnings per share before and after dilution were SEK 1.14 (1.27). Cash flow from operating activities amounted to SEK 34.1 million (17.3). 1 January-30 June 2020 Net...

The information was released for public disclosure on May 29, 2020, at 08:20 CET CellaVision's President and CEO, Zlatko Rihter, has informed the Board of Directors that he wishes to resign as CEO of the company in order to take on the position as President and CEO of the medical technology company Mölnlycke Health Care AB. Zlatko Rihter has been CEO of CellaVision since January 1, 2015. Zlatko will continue in his current role during the notice period and leave his assignment by November 28,...

The information was released for public disclosure on May 26, 2020, at 08:20 CET Today, CellaVision announced that the company's Annual report for 2019 is available as PDF at www.cellavision.com, and can be read via the link below. The company has decided to print CellaVisions 2019 Annual report in a small number of copies in accordance with the company's environmental policy. To request a printed version, please visit the investor pages at CellaVision's website. For further information please...

The information was submitted to the public on May 13, 2020 at 8:20 CET NOTE: This is an unofficial translation of the original notice, which is in Swedish. In case of discrepancies, the Swedish version shall prevail. The shareholders of CellaVision AB (publ) reg. no. 556500-0998 (the “Company”) are hereby summoned to attend the Annual General Meeting (“ AGM ”) on 16 June 2020 at 15.00 CEST at the Company’s premises, at Mobilvägen 12, in Lund, Sweden. Registration starts at 14.30 CEST...

The information was submitted for publication at 08.20 CET on April 22, 2020 January 1 – March 31, 2020 Net sales increased by 29 % to SEK 134.4 million (103.9). Sales grew organically by 1 % (31). EBITDA increased to SEK 41.2 million (38.3). EBITDA margin was 31 % (37). Profit before tax was SEK 25.5 million (34.8). Earnings per share before and after dilution were SEK 0.85 (1.15). Cash flow from operating activities was SEK 15.4 million (51.1). Significant events due to COVID-19 Due to the...

The information was submitted to the public on April 15, 2020 at 8:20 CET CellaVision AB (publ) will publish the Interim report for the first quarter 2020 on April 22, 2020 at 8:20 CET. The report will be available at www.cellavision.com In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CET where Zlatko Rihter, President & CEO, will present and comment the report. The presentation will be in...

The information was submitted for publication March 26, 2020, at. 8.20 (CET) CellaVision's Board of Directors has decided to postpone the AGM until a later date. Furthermore, the company's Board of Directors has decided to withdraw the proposed dividend of SEK 1.50 per share and instead propose that no dividend be paid. CellaVision will submit a new notice to the AGM no later than four weeks before the new date is set. The meeting will be held no later than June 30, in accordance with current...

Annual General Meeting of CellaVision AB (publ) on May 8, 2019 The information was submitted to the public on May 8, 2019 at 20:30 CellaVision AB (publ) held the Annual General Meeting on May 8, 2019 at the company's premises at Mobilvägen 12 in Lund. Determination of income statement and balance sheet and discharge from liability The Annual General Meeting approved the income statement and balance sheet for the Parent Company and the Group for the preceding financial year. The Board members...